1. Scrip
  3. >>Alimentary/Metabolic

A blockbuster is born in J&J's Nucynta ER

 
• By Daniel Chancellor

Johnson & Johnson has received FDA approval for Nucynta ER in moderate to severe chronic pain. Armed with clinical trial data showing comparable efficacy and superior tolerability to the market-leading opioid OxyContin, Nucynta ER is likely to be a commercial success for Johnson & Johnson. Additional benefits in neuropathic pain will further strengthen the clinical argument for its use.

Johnson & Johnson has received FDA approval for Nucynta ER in moderate to severe chronic pain. Armed with clinical trial data showing comparable efficacy and superior tolerability to the market-leading opioid OxyContin, Nucynta ER is likely to be a commercial success for Johnson & Johnson. Additional benefits in neuropathic pain will further strengthen the clinical argument for its use.

The US FDA has approved Johnson & Johnson’s opioid painkiller Nucynta ER (tapentadol extended release) for the management of moderate...

More from Alimentary/Metabolic

More from Therapeutic Category

PureTech Ponders Way Forward As CEO Exits

 
• By Kevin Grogan

Bharatt Chowrira departs days after firm’s chair stepped down.

Sun’s Alopecia Treatment Debuts In US - Can It Make Up For Lost Time?

 
• By Anju Ghangurde

Sun’s Leqselvi goes up against Lilly's Olumiant and Pfizer's Litfulo, which currently has the broadest label, in the US alopecia market. Can it shake things up early, amid growing activity in the space with several new mechanisms of action being investigated?

Kailera Eyes Global Obesity Market With Hengrui’s Phase III Dual Agonist

 
• By Joseph Haas

With China’s Hengrui reporting successful Phase III data for its dual GLP-1/GIP agonist, licensee Kailera is readying plans to demonstrate better efficacy than current obesity drugs.